BPTS - Why Is Penny Stock Biophytis Trading Higher On Tuesday? | Benzinga
Monday, Biophytis SA (NASDAQ:BPTS) announced the launch of a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity combined with GLP-1 receptor agonists.
The OBA Phase 2 clinical study is expected to start in mid-2024, upon regulatory approvals, with the first patients expected to be treated in the second half of 2024.
BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs and following hypocaloric dieting.
With accelerated clinical development, the first efficacy results are expected in 2025.
The company says BIO101 (20-hydroxyecdysone) ...